---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000233"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:48:39.724138+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Terns Pharmaceuticals details 2023 clinical milestones; cash runway to 2026

## Summary
- Plan to initiate US Phase 1 trial for TERN-701 (CML) in H2 2023; top-line readouts 2024. Due to IRA, will not seek US approval for Ph+ ALL.
- Phase 2a DUET trial of TERN-501 (NASH) expects enrollment completion Q1 2023, top-line data Q3 2023; first combo of THR-β and FXR agonist.
- Obesity program TERN-601 (GLP-1 agonist) Phase 1 start H2 2023, top-line data in 2024; preclinical data to be published.
- Cash runway extended to 2026: $293M adjusted cash includes $106M net from Dec 2022 equity offering; excludes potential collaborations.

## SEC filing metadata
- accession: 0000950170-23-000233
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017023000233/0000950170-23-000233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017023000233/tern-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000233
- JSON: https://secwatch.observer/filing/0000950170-23-000233.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.